Measures of Adult Knee Function

McHugh, Michael; Droy, Erin; Muscatelli, Stefano; Gagnier, Joel

doi:10.1002/acr.24235

Cited by 19 publications

(14 citation statements)

References 218 publications

(411 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…When compared with previously reported MDCs for PROMs in knee OA, our average net change in scores for each significant KOOS and OKS value surpassed the 90% confidence interval for the MDC (MDC90). 18,[33][34][35] For the LKS and VAS, however, the MDC90 was surpassed at all time points for each survey, despite statistical significance only being found at 6 weeks and 3 months for LKS and 2 weeks for VAS. 36,37 UCLA also was found to surpass the minimal clinically important difference by 6 weeks and 3 months, despite no statistically significant difference.…”

Section: Discussionmentioning

confidence: 85%

Bioactive Knee Sleeve for Osteoarthritis: A Small Cohort Study

Elphingstone¹,

Paul²,

Girardi³

et al. 2022

Southern Medical Journal

View full text Add to dashboard Cite

Objectives: Osteoarthritis (OA) is one of the most prevalent musculoskeletal ailments worldwide. Numerous conservative therapies exist, but evidence for such treatments remains conflicting. Recently, there has been growing interest surrounding bioactive sleeves for managing knee arthritis; however, the literature on their efficacy for relieving pain and improving function in the setting of knee OA is limited. As such, we sought to investigate the effect of a bioactive sleeve on patient-reported outcome measures in a small cohort of patients with OA.Methods: Patients with knee OAwere given a bioactive sleeve (Reparel, Chico, CA) and asked to refrain from lifestyle modifications and intraarticular corticosteroid injections. Lysholm Knee Score, Oxford Knee Score, Knee Injury and OA Outcome Score (KOOS), Single Assessment Numeric Evaluation, and Visual Analog Scale score were obtained at baseline, 2 weeks, 6 weeks, and 3 months. OA severity was evaluated using the Kellgren and Lawrence (KL) classification system. The Wilcoxon signed rank test was used to compare baseline patient-reported outcomes with 2-week, 6-week, and 3-month time points. Bivariate correlation was used to evaluate the relation between patient-reported outcome measures and KL classification. Results:The cohort was composed of 14 participants-4 males and 10 females-with a mean age of 62.2 ± 13.2 years and a body mass index of 33.7 ± 5.8. The average KL grade was 2.9 (range 2-4). KOOS pain, symptoms, activities of daily living, and quality of life increased significantly at 2 weeks, 6 weeks, and 3 months. KOOS sport and recreation significantly increased at 3 months. The Oxford Knee Score was significantly greater at 2 weeks, 6 weeks, and 3 months. The Lysholm Knee Score was significantly greater at 6 weeks and 3 months. The Single Assessment Numeric Evaluation attained significant improvement at 3 months, and the Visual Analog Scale improvement was significant at 2 weeks. No statistically significant difference was attained with University of California at Los Angeles activity score. Outcome scores did not correlate with KL classification.Conclusions: These data suggest that a bioactive sleeve may improve patient-reported pain, symptoms, and function in the setting of knee OA. Further research is needed to better understand the role of bioactive sleeves for patients with knee arthritis.

show abstract

Section: Discussionmentioning

confidence: 85%

Bioactive Knee Sleeve for Osteoarthritis: A Small Cohort Study

Elphingstone¹,

Paul²,

Girardi³

et al. 2022

Southern Medical Journal

View full text Add to dashboard Cite

show abstract

“…The subscales have multiple 5-point Likert scale questions with responses ranging from 0 (i.e., no dysfunction) to 4 (i.e., worst dysfunction). Each subscale was converted to a score from 0 to 100, with 100 indicating no patient-reported disability (25,26). A PASS threshold for each KOOS subscale has previously been established in participants post-ACLR: symptoms >57.1%, pain >88.9%, QoL >62.5, ADL >100.0%, and sports >75.0 (Table 1) (23).…”

Section: Koosmentioning

confidence: 99%

Prevalence of Early Knee Osteoarthritis Illness Among Various Patient‐Reported Classification Criteria After Anterior Cruciate Ligament Reconstruction

Harkey

Baez

Lewis

et al. 2022

Arthritis Care & Research

View full text Add to dashboard Cite

Objective. To compare the prevalence of participants meeting different patient-reported criteria for early osteoarthritis (OA) illness after anterior cruciate ligament reconstruction (ACLR).Methods. Participants completed the Knee Injury and Osteoarthritis Outcomes Score (KOOS) at a single time point 5.0-7.9 months post-ACLR. We used established KOOS subscale criteria (i.e., Luyten original and Englund original) to define patient-reported early OA illness. A two-by-two contingency table and McNemar's test were used to compare the prevalence of participants who met the Luyten original versus Englund original KOOS criteria for early OA illness. These analyses were repeated using KOOS subscale thresholds based on established population-specific patient acceptable symptom state (PASS) within the Luyten and Englund KOOS criteria (i.e., Luyten PASS and Englund PASS).Results. A greater prevalence of participants with ACLR met the Luyten original criteria (n = 165 [54%]) compared to those who met the Englund original criteria (n = 128 [42%]; χ 2 = 19.3, P < 0.001]). When using the KOOS subscale PASS as thresholds, a significantly greater prevalence of participants with ACLR met the Luyten PASS criteria (n = 133 [43%]) compared to those who met the Englund PASS criteria (n = 85 [28%]; χ 2 = 48.0, P < 0.001). When combining the Luyten and Englund KOOS criteria and using the original/PASS subscale thresholds, respectively, 40%/57% of participants met neither, 24%/15% met only 1, and 36%/28% met both KOOS criteria.Conclusion. Regardless of the classification criteria used to define early OA illness, it is concerning that 28-54% of patients report considerable symptoms ~6 months post-ACLR. Our findings will improve the classification criteria to define early OA illness, which may raise awareness for the need of population-specific criteria.symptom state [PASS] question) 1 and 2 years post-ACLR (mean AE SD age 29.7 AE 11.5 years) (7). Being able to reliably identify

show abstract

“…However, scores for the 10 adult participants (mean 75 ± 19) were significantly lower than those from nonsurgical, age, and sex matched unaffected adults (mean 84.7–95.5 ± 8.2–16.2), indicating more symptoms and poor overall function in our adults with aggrecan deficiency (Anderson et al, 2006; Nasreddine et al, 2017). The minimal detectable change has been reported to be in the 9–16 range for adults and 12 for pediatric IKDC (McHugh et al, 2020). Similarly, the ODI scores for low back pain and function were 0.22 ± 0.67 in pediatric subjects, indicating no disability.…”

Section: Resultsmentioning

confidence: 99%

“…There were no other significant stance phase kinematic differences between affected adult relatives and controls with the exception of stance-related coronal plane (left) knee abduction, which was significantly more abducted (p = 0.03) for controls compared to affected adult relatives (14.7 ± 3.2 vs. 10.2 ± 5.0 ). adults and 12 for pediatric IKDC (McHugh et al, 2020). Similarly, the ODI scores for low back pain and function were 0.22 ± 0.67 in pediatric subjects, indicating no disability.…”

Section: Musculoskeletal Assessment and Imagingmentioning

confidence: 90%

Clinical phenotype and musculoskeletal characteristics of patients with aggrecan deficiency

Alexandrou

Dauber

Tyzinski

et al. 2022

American J of Med Genetics Pt A

View full text Add to dashboard Cite

Aggrecan is a proteoglycan within the physeal and articular cartilage. Aggrecan deficiency, due to heterozygous mutations in the ACAN gene, causes dominantly inherited short stature and, in many patients, early‐onset osteoarthritis and degenerative disc disease. We aimed to further characterize this phenotypic spectrum with an emphasis on musculoskeletal health. Twenty‐two individuals from nine families were enrolled. Histories and examinations focused on joint health, gait analysis, joint specific patient reported outcomes, and imaging studies were performed. All patients had dominantly inherited short stature, with the exception of a de novo mutation. Short stature was worse in adults versus children (median height −3.05 SD vs. −2.25 SD). ACAN mutations were not always associated with bone age advancement (median advancement +1.1 years, range 0 to +2 years). Children had subtle disproportionality and clinically silent joint disease—25% with osteochondritis dissecans (OD). Adults had a high prevalence of joint symptomatology–decline in knee function, disability from spinal complaints, and lower physical activity on outcome measures. Osteoarthritis (OA) and OD was detected in 90% of adults, and orthopedic surgeries were reported in 60%. Aggrecan deficiency leads to short stature with progressive decline in height SD, mild skeletal dysplasia, and increasing prevalence of joint pathology over time. Optimal musculoskeletal health and quality of life can be attained with timely identification of pathology and intervention.

show abstract

Measures of Adult Knee Function

Cited by 19 publications

References 218 publications

Bioactive Knee Sleeve for Osteoarthritis: A Small Cohort Study

Bioactive Knee Sleeve for Osteoarthritis: A Small Cohort Study

Prevalence of Early Knee Osteoarthritis Illness Among Various Patient‐Reported Classification Criteria After Anterior Cruciate Ligament Reconstruction

Clinical phenotype and musculoskeletal characteristics of patients with aggrecan deficiency

Contact Info

Product

Resources

About